Synergistic suppressive effect of double transfection of tumor necrosis factor-α and interleukin 12 genes on tumorigenicity of Meth-A cells

Japanese Journal of Cancer Research

Volumn 91, Issue 12, 2000, Pages 1296-1302

  Fujiwara, Hitoshi ^a,b   Yamauchi, Naofumi ^a,c   Sato, Yasushi ^a   Sasaki, Katsunori ^a   Takahashi, Minoru ^a   Okamoto, Tetsuro ^a   Sato, Tsutomu ^a   Iyama, Satoshi ^a   Koshita, Yoshikazu ^d   Hirayama, Michiaki ^e   Yamagishi, Hisakazu ^b   Niitsu, Yoshiro ^a  

^a SAPPORO MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

^c Sapporo Kiyota Hospital   (Japan)

^d Asari Chuo Hospital   (Japan)

^e Otaru Ekisaikai Hospital   (Japan)

Author keywords

B7.1; Cancer gene therapy; IL 12; MHC class I; TNF

Indexed keywords

3 METHYLCHOLANTHRENE; ANTIBIOTIC G 418; B7 ANTIGEN; BETA GALACTOSIDASE; CANCER VACCINE; CD8 ANTIGEN; CHROMIUM 51; COMPLEMENTARY DNA; CYTOKINE; FLUORESCEIN ISOTHIOCYANATE; HEXADIMETHRINE BROMIDE; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 2; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MONOCLONAL ANTIBODY; NEOMYCIN; OKT 8; PROSTAGLANDIN E2; T LYMPHOCYTE RECEPTOR; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN EXPRESSION; ANTINEOPLASTIC ACTIVITY; ARTICLE; CARCINOGENICITY; CELL ACTIVATION; CELL ACTIVITY; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY TEST; DENDRITIC CELL; DISEASE MODEL; FEMALE; FLUORESCENCE ACTIVATED CELL SORTER; GENETIC TRANSFECTION; IMMUNE RESPONSE; IMMUNOSTIMULATION; IMMUNOSURVEILLANCE; LYMPHOCYTE ACTIVATION; MOUSE; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; TH1 CELL;

ADENOCARCINOMA; ANIMALS; ANTIGENS, CD80; COLONIC NEOPLASMS; CYTOTOXICITY, IMMUNOLOGIC; FIBROSARCOMA; HISTOCOMPATIBILITY ANTIGENS CLASS I; HISTOCOMPATIBILITY ANTIGENS CLASS II; INTERLEUKIN-12; KILLER CELLS, LYMPHOKINE-ACTIVATED; KILLER CELLS, NATURAL; LYMPHOMA; MICE; MICE, INBRED BALB C; RECOMBINANT PROTEINS; T-LYMPHOCYTES, CYTOTOXIC; TRANSFECTION; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0034518033     PISSN: 09105050     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2000.tb00917.x     Document Type: Article

References (26)

1. Inhibition of tumor-specific cytotoxic T lymphocyte responses by transforming growth factor β1
2. Inhibition of cytotoxic T cell development by transforming growth factor β and reversal by recombinant tumor necrosis factor
3. Transforming growth factor-β-induced inhibition of T cell function. Susceptibility difference in T cells of various phenotypes and functions and its relevance to immunosuppression in the tumor-bearing state
4. IL-10 acts on the antigen-presenting cell to inhibit cytokine production by Th1 cells
5. Interleukin-10 down-regulates MHC class II αβ peptide complexes at the plasma membrane of monocytes by affecting arrival and recycling
6. IL-10 prevents the differentiation of monocytes to dendritic cells but promotes their maturation to macrophages
7. Prostaglandin E2 inhibits production of Thl lymphokines but not of Th2 lymphokines
8. IL-12-deficient dendritic cells, generated in the presence of prostaglandin E2, promote type 2 cytokine production in maturing human naive T helper cells
9. Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells
10. Preventing abnormalities in signal transduction of T cells in cancer: The promise of cytokine gene therapy
11. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor α
12. Tumor necrosis factor-α enhances cytolytic activity of human natural killer cells
13. Synergy of tumor necrosis factor and interleukin 2 in the activation of human cytotoxic lymphocytes: Effect of tumor necrosis factor α and interleukin 2 in the generation of human lymphokine-activated killer cell cytotoxicity
14. Efficacy of TNF-α gene-transduced tumor cells in treatment of established in vivo tumor
15. Augmented antitumor effects of killer cells induced by tumor necrosis factor gene-transduced autologous tumor cells from gastrointestinal cancer patients
16. Effects of IL-12 on helper T cell-dependent immune responses in vivo
17. Requirement for Vα14 NKT cells in IL-12-mediated rejection of tumors
18. Administration of recombinant IL-12 to normal mice enhances cytolytic lymphocyte activity and induces production of IFN γ in vivo
19. Influence of interleukin 12 on p53 peptide vaccination against established Meth A sarcoma
20. Antitumor and antimetastatic activity of interleukin 12 against murine tumors
21. Recombinant IL-12 administration induces tumor regression in association with IFN γ production
22. Effective eradication of established murine tumors with IL-12 gene therapy using a polycistronic retroviral vector
23. Expression of endogenous tumor necrosis factor as a protective protein against the cytotoxicity of exogenous tumor necrosis factor
24. Expression of human class-II major histo-compatibility complex antigen using retrovirus vectors
25. Interleukin 12 and tumor necrosis factor α are costimulators of interferon γ production by natural killer cells in severe combined immunodeficiency mice with listeriosis, and interleukin 10 is a physiologic antagonist
26. Characterization of cloned class I MHC-restricted, CD8+ anti-Meth A cytotoxic T-lymphocytes: Recognition of an epitope derived from the Meth A gp110 tumor rejection antigen